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with CF sinonasal diseaseSinonasal complications of cystic fibrosis (CF) such as chronic
rhinosinusitis and nasal polyps can be associated with substantial
morbidity and decreased quality of life for the afflicted. However,
progress in understanding the epidemiology and improving the
management of CF sinonasal disease has suffered in comparison to
that of CF lower airway disease. There are practical aspects to
this disparity: loss of lung function has been a primary cause of
CF mortality for decades and thus a subject of vital interest to
researchers. In truth, progress in improving the management of CF
lower airway disease has been relatively slow and methodical:
seminal observations regarding the role of chronic Pseudomonas
aeruginosa airway infection and accelerated airway disease
progression [1] preceded the first large-scale randomized con-
trolled studies of inhaled antipseudomonal antibiotics [2] and of
‘eradication’ of first P. aeruginosa infection [3] by decades.
Today the lung health of the current CF cohort is markedly
improved over that of past generations, while sinonasal complica-
tions remain clinically important but, by comparison, largely
unstudied. In this issue of the Journal of Cystic Fibrosis, four
original research articles on the epidemiology and management of
CF sinonasal disease are presented. The first, by Berkhout et al.,
explores CFTR mutation classes among patients with sinonasal
complications and suggests a relationship between degree ofCFTR
dysfunction and sinonasal disease severity [4]. The second, by
Wilson et al., compares microflora isolated from the paranasal
sinus and from the lower airways of children, as well as the results
of antibiotic treatment for paranasal sinus bacterial ‘eradication’
[5]. The third and fourth articles describe studies of topical
treatments for CF patients with chronic rhinosinusitis: Di Cicco et
al. report a blinded study comparing the efficacy and tolerability of
hyaluronic acid with and without tobramycin as a nasal spray [6]
and Mainz et al. describe a blinded, placebo-controlled crossover
study of sinonasal dornase alfa administration [7].
Together, these four articles illuminate progress as well as
a need for further CF sinonasal research. On the one hand,
they are testimony to a growing willingness to address difficult
challenges relating to the epidemiology and management of
patients with sinonasal disease. However, they also highlight
both how far behind clinical research is in this area and the
pitfalls of clinical investigation in uncharted waters. The paper
by Berkhort et al. highlights the apparent extent of chronichttp://dx.doi.org/10.1016/j.jcf.2014.05.014
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with milder CFTR mutations, expanding on previous investi-
gations of the relationship of genotype and phenotype for CF
sinonasal disease [8]. This careful analysis of 104 adults from a
single care center highlights the lack of epidemiologic data on
sinonasal disease to be found in our national CF registries. The
submission by Wilson et al. describes the selective culture and
antibiotic ‘eradication’ of bacteria in the sinuses of young,
asymptomatic children with CF. This effort is predicated on a
logic model that paranasal infection in CF predisposes to lower
airway infection, a model that is appealing but for which there
are apparently no observational supportive data. The eradication
procedure these investigators describe was a significant undertak-
ing for the families of these children, a potentially burdensome
treatment regimen based on theory but lacking longitudinal
evidence of benefit. The risks versus benefits entailed in broader
application of such an approach remain unclear, but this is familiar
territory: ‘discussion’ of the risks versus benefits of antistaph-
ylococcal prophylaxis in CF infants using flucloxacillin has
entered its third decade [9]. The study by Di Cicco et al. is
reminiscent of the (very) early days of CF lower airways treat-
ment, but recapitulated in patients with chronic sinonasal disease
comparing hyaluronic acid with and without tobramycin added in
a nasal spray. The treatments were, unfortunately, administered to
dissimilar patient populations with respect to age and microbiol-
ogy and treatment efficacy was evaluated using subjective clinical
endpoints.Without a true placebo control or a validated method for
evaluating response to intervention, how does one draw on these
results when considering the design of the next study? Finally, the
study by Mainz et al. of dornase alfa efficacy employed an aerosol
delivery device designed for the sinuses and a previously described
subjective self-assessment tool (the SNOT-20). The study was
conducted in a fairly heterogeneous population, and it is not
clear whether SNOT-20 has been previously well-characterized in
young people with CF. In addition, crossover designs such as these
have inherent pitfalls and it is possible that functional unblinding
(particularly problematic for subjective endpoints) may have
occurred during this study. These concerns aside, dornase was
found to be beneficial for these patients.
If the CF community is going to realize systematic advances
in the management of sinonasal disease comparable to thosell rights reserved.
362 Editorialalready made for lower airway disease, the path is clear:
a) much better characterization of the epidemiology and natural
history of sinonasal disease is needed, b) these data must be mined
to form hypotheses of disease sequelae and therapeutic approaches
to disease management, c) practical measures of how patients with
sinonasal disease feel and function that lend themselves to study in
different age groups need to be established and validated, and
d) interventionsmust be tested using the same validatedmeasure(s)
in well-designed, randomized, controlled trials that can be incor-
porated into systematic meta-analyses. Many lessons should have
been learned during the multi-decade experience improving the
management of lower airway disease, the most important of which
may be that there are no shortcuts to success. However, in the
interim, persons with CF will continue to experience morbidity
associated with sinonasal disease. To the extent that these four
articles increase CF clinicians' awareness, stimulate hypothesis
formation with respect to disease etiology, and/or encourage
empiric treatment of afflicted individuals to reduce associated
morbidity, then they represent valuable contributions.
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